IPO Year:
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/23/2026 | $31.00 | Overweight | Analyst |
| 4/22/2026 | $40.00 | Overweight | Barclays |
| 4/21/2026 | $45.00 | Buy | UBS |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
3 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
3 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
3 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
4 - First Tracks Biotherapeutics, Inc. (0002091349) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Analyst initiated coverage of First Tracks Biotherapeutics with a rating of Overweight and set a new price target of $31.00
Barclays initiated coverage of First Tracks Biotherapeutics with a rating of Overweight and set a new price target of $40.00
UBS initiated coverage of First Tracks Biotherapeutics with a rating of Buy and set a new price target of $45.00
SCHEDULE 13G - First Tracks Biotherapeutics, Inc. (0002091349) (Subject)